Evidence method
Level · gp.fundamentals.debt_to_revenue
72.17% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
SXTP · Jun 30, 2026
60 DEGREES PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001554855-26-001860General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-1073.47% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
105.98% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
422.30% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
27.32% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-1092.41% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
287.96% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
47.33% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/9 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20254/9 normalizedLevel 3Sep 30, 20256/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 92.56%
- Current
- 72.17%
- Delta
- -20.39%
- Previous
- 18.51%
- Current
- 0.00%
- Delta
- -18.51%
- Previous
- -1691.36%
- Current
- -1073.47%
- Delta
- 617.89%
- Previous
- -0.89%
- Current
- 105.98%
- Delta
- 106.87%
- Previous
- 561.78%
- Current
- 422.30%
- Delta
- -139.49%
- Previous
- 47.12%
- Current
- 27.32%
- Delta
- -19.80%
- Previous
- -1292.45%
- Current
- -1092.41%
- Delta
- 200.04%
- Previous
- 173.64%
- Current
- 287.96%
- Delta
- 114.31%
- Previous
- 76.56%
- Current
- 47.33%
- Delta
- -29.23%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Transitioned To · SXTP Fundamental State →Transitioned To · SXTP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · SXTP CAPEX_INTENSITY_DECREASED →Transitioned To · SXTP CASH_GENERATION_INCREASED →Transitioned To · SXTP GROWTH_INCREASED →Transitioned To · SXTP INVENTORY_PRESSURE_DECREASED →Transitioned To · SXTP MARGIN_DECREASED →Transitioned To · SXTP PROFITABILITY_INCREASED →Transitioned To · SXTP R_AND_D_INTENSITY_INCREASED →Transitioned To · SXTP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.